ICU Medical (ICUI) – Research Analysts’ Weekly Ratings Changes

Posted by Maddie Sorensen on Nov 27th, 2024

ICU Medical (NASDAQ: ICUI) has recently received a number of price target changes and ratings updates:

11/20/2024 – ICU Medical was upgraded by analysts at StockNews.com from a “hold” rating to a “buy” rating.
11/13/2024 – ICU Medical had its price target raised by analysts at KeyCorp from $198.00 to $209.00. They now have an “overweight” rating on the stock.
11/13/2024 – ICU Medical had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
11/12/2024 – ICU Medical was downgraded by analysts at StockNews.com from a “buy” rating to a “hold” rating.
10/15/2024 – ICU Medical had its price target raised by analysts at KeyCorp from $147.00 to $198.00. They now have an “overweight” rating on the stock.
10/14/2024 – ICU Medical is now covered by analysts at Jefferies Financial Group Inc.. They set a “hold” rating and a $183.00 price target on the stock.
10/10/2024 – ICU Medical had its “hold” rating reaffirmed by analysts at Needham & Company LLC.

ICU Medical Trading Up 0.3 %

Shares of NASDAQ ICUI traded up $0.47 during mid-day trading on Wednesday, reaching $158.22. The company had a trading volume of 109,560 shares, compared to its average volume of 273,992. The business’s 50-day moving average is $175.61 and its 200-day moving average is $146.51. The company has a current ratio of 2.29, a quick ratio of 1.03 and a debt-to-equity ratio of 0.75. The stock has a market cap of $3.87 billion, a price-to-earnings ratio of -34.62 and a beta of 0.66. ICU Medical, Inc. has a 52 week low of $83.26 and a 52 week high of $196.26.

Insider Activity at ICU Medical

In other ICU Medical news, VP Daniel Woolson sold 2,502 shares of the company’s stock in a transaction on Friday, August 30th. The stock was sold at an average price of $163.22, for a total transaction of $408,376.44. Following the transaction, the vice president now directly owns 13,107 shares in the company, valued at $2,139,324.54. This represents a 16.03 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Vivek Jain sold 12,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The stock was sold at an average price of $163.46, for a total value of $1,961,520.00. Following the transaction, the chief executive officer now owns 104,593 shares in the company, valued at $17,096,771.78. This trade represents a 10.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 40,464 shares of company stock valued at $6,905,231 in the last three months. 6.70% of the stock is owned by insiders.

Institutional Trading of ICU Medical

Several hedge funds have recently modified their holdings of the stock. Innealta Capital LLC purchased a new position in shares of ICU Medical during the second quarter worth about $32,000. Hexagon Capital Partners LLC grew its holdings in shares of ICU Medical by 162.7% during the third quarter. Hexagon Capital Partners LLC now owns 197 shares of the medical instruments supplier’s stock worth $36,000 after purchasing an additional 122 shares during the last quarter. Allworth Financial LP grew its holdings in shares of ICU Medical by 100.0% during the third quarter. Allworth Financial LP now owns 200 shares of the medical instruments supplier’s stock worth $36,000 after buying an additional 100 shares during the last quarter. Russell Investments Group Ltd. grew its holdings in shares of ICU Medical by 46.4% during the first quarter. Russell Investments Group Ltd. now owns 546 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 173 shares during the last quarter. Finally, Venturi Wealth Management LLC grew its holdings in shares of ICU Medical by 1,510.0% during the third quarter. Venturi Wealth Management LLC now owns 322 shares of the medical instruments supplier’s stock worth $59,000 after buying an additional 302 shares during the last quarter. 96.10% of the stock is currently owned by institutional investors and hedge funds.

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.